关注
Guido Bocci
Guido Bocci
Associate Professor (BIO/14), University of Pisa
在 med.unipi.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs
G Bocci, KC Nicolaou, RS Kerbel
Cancer research 62 (23), 6938-6943, 2002
5772002
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci, G Francia, S Man, J Lawler, RS Kerbel
Proceedings of the National Academy of Sciences 100 (22), 12917-12922, 2003
5332003
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
S Man, G Bocci, G Francia, SK Green, S Jothy, D Hanahan, P Bohlen, ...
Cancer research 62 (10), 2731-2735, 2002
4312002
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma
JML Ebos, G Bocci, S Man, PE Thorpe, DJ Hicklin, D Zhou, X Jia, ...
Molecular cancer research 2 (6), 315-326, 2004
3082004
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci, S Man, SK Green, G Francia, JML Ebos, JM Du Manoir, ...
Cancer research 64 (18), 6616-6625, 2004
2182004
The pharmacological bases of the antiangiogenic activity of paclitaxel
G Bocci, A Di Paolo, R Danesi
Angiogenesis 16, 481-492, 2013
2092013
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
G Bocci, RS Kerbel
Nature Reviews Clinical Oncology 13 (11), 659-673, 2016
2012016
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
F Crea, L Fornaro, G Bocci, L Sun, WL Farrar, A Falcone, R Danesi
Cancer and Metastasis Reviews 31, 753-761, 2012
1802012
High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata
A Fasciani, G D'ambrogio, G Bocci, M Monti, AR Genazzani, PG Artini
Molecular Human Reproduction 6 (1), 50-54, 2000
1552000
Cyclophosphamide-methotrexate ‘metronomic’chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
G Bocci, M Tuccori, U Emmenegger, V Liguori, A Falcone, RS Kerbel, ...
Annals of oncology 16 (8), 1243-1252, 2005
1532005
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
A Di Paolo, R Danesi, A Falcone, L Cionini, F Vannozzi, G Masi, ...
Annals of oncology 12 (9), 1301-1306, 2001
1532001
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
N Penel, A Adenis, G Bocci
Critical reviews in oncology/hematology 82 (1), 40-50, 2012
1512012
Periorbital necrotising fasciitis
D Lazzeri, S Lazzeri, M Figus, C Tascini, G Bocci, L Colizzi, G Giannotti, ...
British Journal of Ophthalmology 94 (12), 1577-1585, 2010
1382010
Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995).
R Danesi, C Agen, U Benelli, AD Paolo, D Nardini, G Bocci, F Basolo, ...
Clinical cancer research: an official journal of the American Association …, 1997
1361997
Scholars and scientists in the history of the lymphatic system
G Natale, G Bocci, D Ribatti
Journal of anatomy 231 (3), 417-429, 2017
1242017
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5, 6-dihydrouracil after conventional and reduced test dose in cancer patients
G Bocci, R Danesi, A Di Paolo, F Innocenti, G Allegrini, A Falcone, ...
Clinical cancer research 6 (8), 3032-3037, 2000
1242000
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
G Bocci, A Falcone, A Fioravanti, P Orlandi, A Di Paolo, G Fanelli, ...
British journal of cancer 98 (10), 1619-1629, 2008
1132008
Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification
A Di Paolo, G Bocci
Current oncology reports 9, 109-114, 2007
1102007
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ...
British journal of cancer 104 (8), 1262-1269, 2011
1092011
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer
A Fontana, L Galli, A Fioravanti, P Orlandi, C Galli, L Landi, S Bursi, ...
Clinical Cancer Research 15 (15), 4954-4962, 2009
1052009
系统目前无法执行此操作,请稍后再试。
文章 1–20